NOTCH3 and Pulmonary Arterial Hypertension

被引:1
|
作者
Winicki, Nolan M. [1 ]
Puerta, Cristian [1 ]
Besse, Casandra E. [1 ]
Zhang, Yu [1 ]
Thistlethwaite, Patricia A. [1 ]
机构
[1] Univ Calif San Diego, Div Cardiothorac Surg, 9300 Campus Point Dr, La Jolla, CA 92037 USA
关键词
NOTCH3; pulmonary arterial hypertension; JAG-1; DLL-4; PAH; HES-5; Notch3; GAMMA-SECRETASE; RODENT MODELS; OPEN-LABEL; ACTIVATION; INHIBITORS; DEMCIZUMAB; PROMOTES;
D O I
10.3390/ijms25116248
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
NOTCH3 receptor signaling has been linked to the regulation of smooth muscle cell proliferation and the maintenance of smooth muscle cells in an undifferentiated state. Pulmonary arterial hypertension (World Health Organization Group 1 idiopathic disease: PAH) is a fatal disease characterized clinically by elevated pulmonary vascular resistance caused by extensive vascular smooth muscle cell proliferation, perivascular inflammation, and asymmetric neointimal hyperplasia in precapillary pulmonary arteries. In this review, a detailed overview of the specific role of NOTCH3 signaling in PAH, including its mechanisms of activation by a select ligand, downstream signaling effectors, and physiologic effects within the pulmonary vascular tree, is provided. Animal models showing the importance of the NOTCH3 pathway in clinical PAH will be discussed. New drugs and biologics that inhibit NOTCH3 signaling and reverse this deadly disease are highlighted.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Scleroderma pulmonary arterial hypertension: the same as idiopathic pulmonary arterial hypertension?
    Khan, Sarah L.
    Mathai, Stephen C.
    CURRENT OPINION IN PULMONARY MEDICINE, 2023, 29 (05) : 380 - 390
  • [22] Lysosome-dependent degradation of Notch3
    Jia, Lijun
    Yu, Genggeng
    Zhang, Yanmei
    Wang, Michael M.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (12): : 2594 - 2598
  • [23] Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension
    Guo, Shaomei
    Feng, Ziming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 15302 - 15307
  • [24] Role of macrophages in pulmonary arterial hypertension
    Zhang, Meng-Qi
    Wang, Chen-Chen
    Pang, Xiao-Bin
    Shi, Jun-Zhuo
    Li, Hao-Ran
    Xie, Xin-Mei
    Wang, Zhe
    Zhang, Hong-Da
    Zhou, Yun-Feng
    Chen, Ji-Wang
    Han, Zhi-Yan
    Zhao, Lu-Ling
    He, Yang-Yang
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] Numb regulates Notch1, but not Notch3, during myogenesis
    Beres, Brian J.
    George, Rajani
    Lougher, Eric J.
    Barton, Michael
    Verrelli, Brian C.
    McGlade, C. Jane
    Rawls, J. Alan
    Wilson-Rawls, Jeanne
    MECHANISMS OF DEVELOPMENT, 2011, 128 (5-6) : 247 - 257
  • [26] Pharmacologic Treatment of Pulmonary Arterial Hypertension
    Ramani, Gautam V.
    Gill, Sartraj
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (22) : 3963 - 3973
  • [27] Proteomic analysis of pulmonary arterial hypertension
    Qin, Xiaohan
    Li, Tianhao
    Sun, Wei
    Guo, Xiaoxiao
    Fang, Quan
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2021, 12
  • [28] Combination Therapy in Pulmonary Arterial Hypertension
    Pugh, Meredith E.
    Hemnes, Anna R.
    Robbins, Ivan M.
    CLINICS IN CHEST MEDICINE, 2013, 34 (04) : 841 - +
  • [29] Immune Cells in Pulmonary Arterial Hypertension
    Ni, Silu
    Ji, Tiantian
    Dong, Jiarui
    Chen, Fengqiang
    Feng, Hao
    Zhao, Huiying
    Chen, Dekun
    Ma, Wentao
    HEART LUNG AND CIRCULATION, 2022, 31 (07): : 934 - 943
  • [30] Targeting sphingosine kinase 1 for the treatment of pulmonary arterial hypertension
    Yang, Kan
    Jiang, Kaixuan
    Xu, Zhengwen
    Song, Yali
    Wang, Jinxin
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (22) : 2939 - 2953